Experience

Davis Polk advised Natura Cosméticos S.A. in connection with its $750 million offering of 5.375% senior notes due 2023, which were issued pursuant to Rule 144A and Regulation S under the…

Davis Polk is advising the joint lead arrangers, joint bookrunners and the administrative agent in connection with a $2.5 billion unsecured bridge facility to be…

Davis Polk advised Grupo Financiero Santander México, S.A.B. de C.V. (“Grupo Financiero Santander México”) and Banco Santander (México), S.A., Institución de Banca Múltiple, Grupo…

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to Varian Medical Systems, Inc. in connection with its approximately A$1.6 billion acquisition of Sirtex Medical…

Davis Polk advised Auris Medical Holding AG on its registered direct offering of 12,499,999 of its common shares and concurrent private placement of warrants to purchase up to 7,499,999 of…

Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc. The common stock is listed on the…

Davis Polk advised one of the joint global coordinators for the placement of up to 450,000,000 new shares in Beijing Enterprises Water Group Limited (“BEWGL”) for a total consideration of…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 13,333,333 shares of common stock of ConforMis,…

Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of CAD500 million aggregate principal amount of floating-rate senior notes due 2021. The notes,…

Davis Polk advised the joint book-running managers in connection with a $115 million SEC-registered offering of 5,897,435 shares of common stock of Five Prime Therapeutics, Inc. The…